Next Article in Journal
New Horizons in Antifungal Therapy
Next Article in Special Issue
Correction: Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi 2016, 2, 25.
Previous Article in Journal
Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery
Previous Article in Special Issue
PCR Technology for Detection of Invasive Aspergillosis
Article Menu

Export Article

Correction published on 4 November 2016, see J. Fungi 2016, 2(4), 27.

Open AccessReview
J. Fungi 2016, 2(3), 25; doi:10.3390/jof2030025

Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence

1
Department of Internal Medicine, Division of Infectious Diseases, Davis Medical Center, 4150 V Street, Suite G500, Sacramento, CA 95817, USA
2
Department of Medical Microbiology and Immunology, University of California, Rm. 3138, Tupper Hall, One Shields Ave, Davis, CA 95616, USA
*
Author to whom correspondence should be addressed.
Academic Editor: William J. Steinbach
Received: 16 May 2016 / Revised: 25 August 2016 / Accepted: 1 September 2016 / Published: 8 September 2016
(This article belongs to the Special Issue Aspergillus fumigatus: From Diagnosis to Therapy)
View Full-Text   |   Download PDF [202 KB, uploaded 4 November 2016]

Abstract

Aspergillus spp. are a group of filamentous molds that were first described due to a perceived similarity to an aspergillum, or liturgical device used to sprinkle holy water, when viewed under a microscope. Although commonly inhaled due to their ubiquitous nature within the environment, an invasive fungal infection (IFI) is a rare outcome that is often reserved for those patients who are immunocompromised. Given the potential for significant morbidity and mortality within this patient population from IFI due to Aspergillus spp., along with the rise in the use of therapies that confer immunosuppression, there is an increasing need for appropriate initial clinical suspicion leading to accurate diagnosis and effective treatment. Voriconazole remains the first line agent for therapy; however, the use of polyenes, novel triazole agents, or voriconazole in combination with an echinocandin may also be utilized. Consideration as to which particular agent and for what duration should be made in the individual context for each patient based upon underlying immunosuppression, comorbidities, and overall tolerance of therapy. View Full-Text
Keywords: aspergillosis; treatment; voriconazole; isavuconazole; combination therapy; posacaonzole; echinocandins aspergillosis; treatment; voriconazole; isavuconazole; combination therapy; posacaonzole; echinocandins
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi 2016, 2, 25.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Fungi EISSN 2309-608X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top